Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Tecelra (afamitresgene autoleucel)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Adaptimmune

Drug class:

TCR modulator, MAGE-A4 inhibitor

Related drugs:

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

ADP-A2M4CD8 (1)

MultiTAA T cell therapy (0)

FH-TCR-Tᴍsʟɴ (0)

HA-1 T TCR T Cell Immunotherapy (0)

MAGE A3 TCR (0)

NY-ESO-1 TCR (0)

NY-ESO-1 TCR-T cell therapy (0)

T-Plex-200-A0201/204-A0201 (0)

T-cell receptor therapy (0)

TSC-200-A0201 (0)

TSC-204-A0201 (0)

TSC-204-C0702 (0)

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

ADP-A2M4CD8 (1)

MultiTAA T cell therapy (0)

›

MAGEA4 expression	Synovial Sarcoma	MAGEA4 expression	Synovial Sarcoma	afamitresgene autoleucel Sensitive: A1 - Approval afamitresgene autoleucel Sensitive : A1	afamitresgene autoleucel Sensitive: A1 - Approval afamitresgene autoleucel Sensitive : A1
HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3
HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3